Morgan Stanley Maintains Overweight on Cytokinetics, Raises Price Target to $103
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Morgan Stanley analyst Jeffrey Hung maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $90 to $103.
Morgan Stanley analyst Jeffrey Hung maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $90 to $103.